What Thermo Fisher Scientific Investors Are Talking About Today.

Large-cap Industrials company Thermo Fisher Scientific has moved 0.2% so far today on a volume of 198,327, compared to its average of 1,897,282. In contrast, the S&P 500 index moved 0.0%.

Thermo Fisher Scientific trades -2.85% away from its average analyst target price of $554.4 per share. The 23 analysts following the stock have set target prices ranging from $435.0 to $640.0, and on average have given Thermo Fisher Scientific a rating of buy.

Anyone interested in buying TMO should be aware of the facts below:

  • Thermo Fisher Scientific's current price is 179.0% above its Graham number of $193.06, which implies that at its current valuation it does not offer a margin of safety

  • Thermo Fisher Scientific has moved 0.4% over the last year, and the S&P 500 logged a change of 20.4%

  • Based on its trailing earnings per share of 15.53, Thermo Fisher Scientific has a trailing 12 month Price to Earnings (P/E) ratio of 34.7 while the S&P 500 average is 15.97

  • TMO has a forward P/E ratio of 24.4 based on its forward 12 month price to earnings (EPS) of $22.03 per share

  • The company has a price to earnings growth (PEG) ratio of 11.87 — a number near or below 1 signifying that Thermo Fisher Scientific is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 4.59 compared to its sector average of 4.06

  • Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally.

  • Based in Waltham, the company has 130,000 full time employees and a market cap of $208.09 Billion. Thermo Fisher Scientific currently returns an annual dividend yield of 0.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.